A comparative review of Haute Autorité de Santé and National Institute for Health and Care Excellence health technology assessments of Ikervis® to treat severe keratitis in adult patients with dry eye disease which has not improved despite treatment with tear substitutes.

The human burden of disease remains quite significant compared to other medical conditions, as it has been reported that patients without co-morbidities expecting to live 10 more years would give up 1.6 years of that time to be rid of severe DED, which puts the disease on the same burden level as moderate to severe (class III–IV) angina [ 14 ].

also in 5,695 other papers